Table 1 Baseline clinical characteristics of all subjects
| Â | Control | Diabetes | UAP(DM) | UAP(non-DM) | P Value |
|---|---|---|---|---|---|
(n=36) | (n=42) | (n=23) | (n=34) | ||
Age (years) | 59.2 ± 7.5 | 55.92 ± 14.72 | 59.3 ± 8.65 | 60.52 ± 9.86 | NS |
Male, n (%) | 21 (58) | 23 (57) | 14 (61) | 22 (64) | NS |
Smoking, n (%) | 11 (30) | 13 (31) | 8 (34) | 13 (38) | NS |
Hypertension n (%) | 0 (0) | 17 (40) | 14 (60) | 18 (53) | < 0.01 |
Total cholesterol (mmol/l) | 4.37 ± 1.23 | 4.69 ± 1.02 | 4.40 ± 1.12 | 4.62 ± 1.35 | NS |
HDL cholesterol (mmol/l) | 1.25 ± 0.46 | 1.30 ± 0.40 | 1.32 ± 0.42 | 1.53 ± 0.54 | NS |
LDL cholesterol (mmol/l) | 2.83 ± 0.96 | 3.07 ± 0.823 | 2.53 ± 1.44 | 2.75 ± 1.05 | NS |
Triglycerides (mmol/l) | 1.65 ± 1.32 | 1.95 ± 1.50 | 1.89 ± 1.76 | 1.79 ± 1.68 | NS |
HbA1c (%) | - | 9.09 ± 3.01 | 8.33 ± 3.52 | 5.62 ± 0.86 | < 0.01 |
FBG (mmol/L) | 5.36 ± 1.82 | 11.84 ± 6.67 | 8.3 ± 4.1 | 6.13 ± 1.34 | < 0.01 |
PBG2h (mmol/L) | - | 14.55 ± 7.75 | 11.23 ± 6.31 | 7.32 ± 1.51 | < 0.01 |
Diabetes duration (year) | - | 5.61 ± 2.95 | 6.48 ± 3.62 | - | NS |
Medications, n (%) | |||||
Insulin | - | 6 (14) | 3 (13) | - | NS |
Antidiabetics | - | 19 (45) | 13 (56) | - | NS |
Statin | - | 15 (35) | 19 (83) | 26 (76) | < 0.01 |
Aspirin | - | 17 (40) | 21 (91) | 29 (85) | < 0.01 |
Clopidogrel | - | 0 (0) | 5 (22) | 6 (18) | < 0.01 |
ACE inhibitor | - | 11 (26) | 12 (52) | 16 (47) | < 0.01 |
Beta-receptors blocker | - | 3 (7) | 7 (30) | 13 (38) | < 0.01 |
Nitroglycerin | - | 0 (0) | 8 (35) | 13 (38) | < 0.01 |